Under the commitment, GSK will supply doses of Cervarix (Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)) to four new GAVI demonstration projects at reasonably discounted rate.
GSK Vaccines president and general manager Christophe Weber said, "Cervical cancer is a significant issue especially in poorer countries where the availability of screening is limited. We are pleased to be expanding our commitment to GAVI by delivering our Cervarix vaccine to help protect girls in the developing world."
The GAVI demonstration programmes, expected to construct experience in delivering the vaccines to girls nine years of age and older, are scheduled to begin shortly.
The countries will be able to assess their ability to roll out national immunisation programmes through the demonstration programmes.
The GAVI Alliance CEO Dr Seth Berkley said, "A vast gap currently exists between girls in rich and poor countries. With GAVI’s programmes we can begin to bridge that gap so that all girls can be protected against cervical cancer no matter where they are born."